David Ramsey, MD, PhD, MPH, previews a session at the American Academy of Ophthalmology 2021 conference that explores whether telehealth visits among patients with diabetes affected rates of completed in-person eye examinations.
As the COVID-19 pandemic was the first time we delivered telehealth services, we didn't know what benefit it might have for our patients, said David Ramsey, MD, PhD, MPH, an ophthalmologist and director of ophthalmic research at Lahey Hospital and Medical Center of Beth Israel Lahey Health. Ramsey will present research during an American Academy of Ophthalmology 2021 session called, "Telehealth Encourages More Minority Patients With Diabetes to Return for In-Person Care During the COVID-19 Pandemic." Research coauthors include Karen Latulippe; Jeffrey L. Marx, MD; Shiyoung Roh, MD; Claudia C. Lasalle; Sidrah Anjum; and Ed Momplaisir.
Transcript:
Could you introduce yourself and explain the work you do?
Hi, I'm David Ramsey, MD, PhD, MPH. I'm an ophthalmologist at the Lahey Hospital and Medical Center, a part of Beth Israel Lahey Health. I work as a vitreoretinal surgeon. I'm the director of ophthalmic research at the Lahey Hospital and the Harry Lee Chair of Innovation. I work in the area of retina, providing care to patients with diabetes, macular degeneration, retinal detachments, and other surgical diseases as well.
What are you hoping attendees will learn at AAO 2021?
At the American Academy this year, we hope to share with those who attend our presentation, our findings regarding telehealth and the beneficial effect it had on patients, specifically those with diabetes and diabetic retinopathy. The COVID-19 pandemic was the first time we delivered telehealth service on any scale. We didn't know what sort of benefit this might have for our patients. What we're hoping to share is, one of the positive outcomes of this study looking back retrospectively, was that patients who received telehealth services were very much more likely to return for in-person diabetic eye exams in the first year of the pandemic.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More